

DAFTAR PUSTAKA

- A, D. H. K. *et al.* (2020) 'A Case Report on Metformin and Insulin Induced Hypoglycemia', *Archives of Medicine*, 12(3), pp. 10–12. doi: 10.36648/1989-5216.12.3.307.
- Abdel-Latif, M. M. M. and Abdel-Wahab, B. A. (2015) 'Knowledge and awareness of adverse drug reactions and pharmacovigilance practices among healthcare professionals in Al-Madinah Al-Munawwarah, Kingdom of Saudi Arabia', *Saudi Pharmaceutical Journal*. doi: 10.1016/j.jsps.2014.07.005.
- Ajayi, F. O., Sun, H. and Perry, J. (2000) 'Adverse drug reactions: A review of relevant factors', *Journal of Clinical Pharmacology*. doi: 10.1177/009127000004001003.
- Allemann, S. S. *et al.* (2014) 'Pharmaceutical care: The PCNE definition 2013', *International Journal of Clinical Pharmacy*. doi: 10.1007/s11096-014-9933-x.
- Almasdy, D. *et al.* (2015) 'Evaluasi Penggunaan Obat Antidiabetik Pada Pasien Diabetes Melitus Tipe-2 di Suatu Rumah Sakit Pemerintah Kota Padang – Sumatera Barat', *Jurnal Sains Farmasi & Klinis*. doi: 10.29208/jsfk.2015.2.1.58.
- Amin, S. *et al.* (2018) 'An analysis of adverse drug reactions in extremes of age group at tertiary care teaching hospital', *Perspectives in Clinical Research*. doi: 10.4103/picr.PICR-64-17.
- Aymanns, C. *et al.* (2010) 'Review on pharmacokinetics and pharmacodynamics and the aging kidney', *Clinical Journal of the American Society of Nephrology*. doi: 10.2215/CJN.03960609.
- Bawazir, S. A. (2006) 'Attitude of community pharmacists in Saudi Arabia towards adverse drug reaction reporting', *Saudi Pharmaceutical Journal*.
- Bond, C. A. and Raehl, C. L. (2006) 'Adverse drug reactions in United States hospitals', *Pharmacotherapy*. doi: 10.1592/phco.26.5.601.
- Bouvy, J. C., De Bruin, M. L. and Koopmanschap, M. A. (2015) 'Epidemiology of Adverse Drug Reactions in Europe: A Review of Recent Observational Studies', *Drug Safety*. doi: 10.1007/s40264-015-0281-0.
- BPOM RI (2014) *PETUNJUK OPERASIONAL PENERAPAN PEDOMAN CARA PEMBUATAN OBAT YANG BAIK, JILID II*, *Bpom*. doi: 10.1017/CBO9781107415324.004.
- BPOM RI (2020) Modul Farmakovigilans Untuk Tenaga Profesional Kesehatan. BPOM
- Bracken, L. *et al.* (2014) 'PO-0926 Are Group Assessments Superior To Individual Avoidability Assessments? A Test Of The Liverpool Adverse Drug

- Reaction Avoidability Assessment Tool', *Archives of Disease in Childhood*. doi: 10.1136/archdischild-2014-307384.1547.
- Bracken, L. E. *et al.* (2017) 'Development of the Liverpool adverse drug reaction avoidability assessment tool', *PLoS ONE*, 12(1), pp. 1–11. doi: 10.1371/journal.pone.0169393.
- Buck, M. D. *et al.* (2009) 'Potentially inappropriate medication prescribing in outpatient practices: Prevalence and patient characteristics based on electronic health records', *American Journal Geriatric Pharmacotherapy*. doi: 10.1016/j.amjopharm.2009.03.001.
- Chan, D.-C. *et al.* (2012) 'Drug-related problems (DRPs) identified from geriatric medication safety review clinics.', *Archives of gerontology and geriatrics*. Netherlands, 54(1), pp. 168–174. doi: 10.1016/j.archger.2011.02.005.
- Chan, M., Nicklason, F. and Vial, J. H. (2001) 'Adverse drug events as a cause of hospital admission in the elderly', *Internal Medicine Journal*. doi: 10.1046/j.1445-5994.2001.00044.x.
- Chandrappa, S., R. D. and Rajarathna, K. (2018) 'Assessing prescriptions for potentially inappropriate medications using Beer's criteria in elderly in-patients at a tertiary care hospital', *National Journal of Physiology, Pharmacy and Pharmacology*. doi: 10.5455/njppp.2019.9.1236011122018.
- Chrischilles, E. *et al.* (2007) 'Risk factors for adverse drug events in older adults with mobility limitations in the community setting', *Journal of the American Geriatrics Society*. doi: 10.1111/j.1532-5415.2006.01034.x.
- Cipolle, R. J., Strand, L. M., Morley, P. C. (2012) 'Pharmaceutical Care as a Professional Practice for Patient-Centered Medication Management Services', in *Pharmaceutical Care Practice - The Patient-Centered Approach to Medication Management Services*.
- Coleman, K., Heller, S. and Leventhal, L. (2003) 'Something old, something new: Designing for the Aging Population', *Health bulletin*.
- Departemen Kesehatan (2015) 'Departemen Kesehatan RI', *Journal of Chemical Information and Modeling*. doi: 10.1017/CBO9781107415324.004.
- Egger, S. S. *et al.* (2010) 'Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT', *Bone Marrow Transplantation*, 45(7), pp. 1197–1203. doi: 10.1038/bmt.2009.325.
- European Medicines Agency (2014) 'Guidelines on good pharmacovigilance practices (GVP): Module V – Risk management systems (Rev 1)', *EMA/838713/2011 Rev 1**.
- Ferrucci, L., Giallauria, F. and Guralnik, J. M. (2008) 'Epidemiology of Aging', *Radiologic Clinics of North America*. doi: 10.1016/j.rcl.2008.07.005.

- Fick, D. M. *et al.* (2019) ‘American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults’, *Journal of the American Geriatrics Society*. doi: 10.1111/jgs.15767.
- Field, T. S. *et al.* (2004) ‘Risk factors for adverse drug events among older adults in the ambulatory setting’, *Journal of the American Geriatrics Society*. doi: 10.1111/j.1532-5415.2004.52367.x.
- Holman, C. (2019) ‘Beers Criteria Updates: New Guidance for Geriatric Medication Safety’, *Clinical drug information*. Wolters Kluwer.
- Isnani, N. and Mulyani, M. (2018) ‘Pengaruh Karakteristik Pasien Dengan Terjadinya Adverse Drug Reaction (ADR) Pada Pasien Diabetes Melitus Tipe 2 Rawat Inap Di Rsud Dr. H. Moch. Ansari Saleh Banjarmasin’, *Jurnal Mandala Pharmacon Indonesia*, 4(1), pp. 1–6. doi: 10.35311/jmpi.v4i1.16.
- Julie Louise Gerberding, Patricia P. Barry, T. F. W. (2004) ‘The State of Aging and Health in America’, p. 48. Available at: http://www.cdc.gov/aging/pdf/state_of_aging_and_health_in_america_2004.pdf.
- Juwita, D. A., Arifin, H. and Putri, A. R. (2016) ‘Association between individual characteristics and health related quality of life (hrqol) in patient with type 2 diabetes mellitus’, *Research Journal of Pharmaceutical, Biological and Chemical Sciences*.
- Kemenkes RI (2013) ‘Buletin Lansia’, *Kementerian Kesehatan Republik Indonesia*.
- Kemenkes RI (2017) ‘Analisis Lansia di Indonesia’, *Pusat data dan informasi Kementerian Kesehatan RI*.
- Kementerian Kesehatan Republik Indonesia (2013) ‘Hasil Riset Kesehatan Dasar Kementerian RI 2013’, *Proceedings, Annual Meeting - Air Pollution Control Association*. doi: 1 Desember 2013.
- Kementrian Kesehatan Republik Indonesia (2017) ‘Peraturan Menteri Kesehatan Republik Indonesia Nomor 72 Tahun 2016 Tentang Standar Pelayanan Kefarmasian’, *Peraturan Menteri Kesehatan Republik Indonesia Nomor 72 Tahun 2016*, (May), pp. 31–48.
- Khan, L. M., Al-Harhi, S. E. and Saadah, O. I. (2013) ‘Adverse drug reactions in hospitalized pediatric patients of Saudi Arabian University Hospital and impact of pharmacovigilance in reporting ADR’, *Saudi Pharmaceutical Journal*. doi: 10.1016/j.jsps.2012.09.004.
- Kim, J. H. and Scialli, A. R. (2011) ‘Thalidomide: The tragedy of birth defects and the effective treatment of disease’, *Toxicological Sciences*. doi: 10.1093/toxsci/kfr088.
- Kojima, T. *et al.* (2020) ‘Risk factors for adverse drug reactions in older inpatients of geriatric wards at admission: Multicenter study’, *Geriatrics and*

- Gerontology International*, 20(2), pp. 144–149. doi: 10.1111/ggi.13844.
- Kudri, A. M. and Barliana, M. I. (2018) 'Pengetahuan dan Kesadaran Apoteker dan Pasien dalam Melaporkan Adverse Drug Reaction (ADR) terhadap Keamanan Obat', *Farmaka*, 16(2), pp. 525–530. Available at: <http://jurnal.unpad.ac.id/farmaka/article/view/17602>.
- Little, W. *et al.* (2012) *Introduction to Sociology-1st Canadian edition, BC Open Textbook*. doi: 10.1021/ja0469378.
- Lövborg, H. *et al.* (2012) 'A prospective analysis of the preventability of adverse drug reactions reported in Sweden', *European Journal of Clinical Pharmacology*. doi: 10.1007/s00228-012-1237-2.
- Mahajan, S., Tandon, V. R. and Kumar, S. (2011) 'Women & risk for developing ADR's', *JK Science*, 14(1), p. 1.
- Mallet, L., Spinewine, A. and Huang, A. (2007) 'The challenge of managing drug interactions in elderly people', *Lancet*. doi: 10.1016/S0140-6736(07)61092-7.
- Manzella, D. (2019) 'How Comorbid Conditions Can Affect Your Diabetes Care', *Verywell Health*.
- Meilani, D. and Sinuraya, R. K. (2018) 'Pharmacovigilance Dalam Aspek Penanganan Reaksi Obat Yang Tidak Diinginkan: Sebuah Artikel Review', *Farmaka*, 16(Vol 16, No 1 (2018): Farmaka (Juni)), pp. 103–112. Available at: <http://jurnal.unpad.ac.id/farmaka/article/view/17037>.
- Modig, S. and Elmståhl, S. (2018) 'Kidney function and use of nonsteroidal anti-inflammatory drugs among elderly people: a cross-sectional study on potential hazards for an at risk population.', *International journal of clinical pharmacy*, 40(4), pp. 870–877. doi: 10.1007/s11096-018-0598-8.
- No 79, P. (2014) 'Penyelenggaraan Pelayanan Geriatri di Rumah Sakit', in *Cell*. doi: 10.1016/j.cell.2009.01.043.
- Noviarny, D. (2016) 'Pengenalan Farmakovigilans, Apa dan Mengapa Diperlukan?', *Medicinus*, 29(1).
- Odegard, P. S. *et al.* (2007) 'Geriatric pharmacy education: A strategic plan for the future', *American Journal of Pharmaceutical Education*. doi: 10.5688/aj710347.
- Rahmatini, R. (2015) 'EVALUASI KHASIAT DAN KEAMANAN OBAT (UJI KLINIK)', *Majalah Kedokteran Andalas*. doi: 10.22338/mka.v34.i1.p31-38.2010.
- Rosa, M., Armenia, A. and Almasdy, D. (2015) 'Impact of social demography characteristics, and antihypertensive medication adherence to the HRQoL on the congestive heart failure patients', *Jurnal Sains Farmasi*

& *Klinis*.

- Rovner, J. (2013) 'Agency for Toxic Substances and Disease Registry (ATSDR)', in *Health Care Policy and Politics A to Z*. doi: 10.4135/9781452240121.n18.
- Rsdjamil.co.id (2020) *RSUP Dr. M. Djamil*. Available at: <http://www.rsdjamil.co.id/>.
- States, M., Draft, E. F. G. and Start, E. (2012) 'Guideline on good pharmacovigilance practices (GVP)', *Reg.S09*. doi: EMA/876333/2011 Rev. 1*.
- Stephens, M. D. ., Talbot, J. C. . and Routledge, P. . (1998) *Detection of New Adverse Drug Reactions*. Fourth Edi. New York: Grove's Dictionaries Inc.
- Suryawati (2014) 'Farmakovigilans dan Peran Perawat Untuk Keamanan Pasien', *Idea Nursing Journal*, 5(3), pp. 40–45.
- Tan, J. L. *et al.* (2015) 'Age-Related Changes in Hepatic Function: An Update on Implications for Drug Therapy.', *Drugs & aging*. New Zealand, 32(12), pp. 999–1008. doi: 10.1007/s40266-015-0318-1.
- Tangiisuran, B. *et al.* (2010) 'Adverse drug reactions in older people', *Reviews in Clinical Gerontology*. doi: 10.1017/S0959259810000171.
- The America Geriatrics Society 2015 Beers Criteria Update Expert Panel (2015) 'American Geriatrics Society 2015 Updated Beers Criteria for', *JAGS*. doi: 10.1111/jgs.13702.
- Tobat, S. R., Muchtar, M. H. and Martini, R. D. (2016a) 'IDENTIFIKASI ADR (ADVERSE DRUG REACTION) PADA PASIEN GERIATRI di BAGIAN/SMF RAWAT INAP PENYAKIT DALAM RSUP. DR.M.DJAMIL PADANG', *Scientia : Jurnal Farmasi dan Kesehatan*. doi: 10.36434/scientia.v5i1.70.
- Tobat, S. R., Muchtar, M. H. and Martini, R. D. (2016b) 'IDENTIFIKASI ADR (ADVERSE DRUG REACTION) PADA PASIEN GERIATRI di BAGIAN/SMF RAWAT INAP PENYAKIT DALAM RSUP. DR.M.DJAMIL PADANG', *Scientia : Jurnal Farmasi dan Kesehatan*, 5(1), p. 57. doi: 10.36434/scientia.v5i1.70.
- Tune, L. E. (2001) 'Anticholinergic effects of medication in elderly patients', in *Journal of Clinical Psychiatry*.
- U.S. Food and Drug Administration (2015) 'Table of Pharmacogenomic Biomarkers in Drug Labeling', <Http://Www.Fda.Gov/Drugs/Scienceresearch/Researchareas/Pharmacogenetics/Ucm083378.Htm>. doi: 08/18/2014.
- WHO (2006) 'The Safety of Medicines in Public health programmes: Pharmacovigilance an essential tool', *WHO Library Cataloguing-in-Publication Data*.

Widyati (2019) *Praktik Farmasi Klinik*. Surabaya: Uwais Inspirasi Indonesia.

World Health Organization (2002) *The Importance of Pharmacovigilance - Safety Monitoring of medicinal products*, Who. doi: 10.1002/0470853093.

